Rob Sands
Analyst · Wells Fargo. Your line is open
Thank you, Patty. Good morning and welcome to our discussion of Constellation’s second quarter sales and earnings results. I would like to kick off the call with a reminder that Constellation has an outstanding core business that consistently delivers top tier growth within the consumers’ product space as reinforced by our second quarter double-digit organic net sales and comparable EPS results. These results were driven by the Constellation beer business, which delivered exceptional performance with industry-leading depletion growth of 10% and record operating margin results. During the quarter, our beer business was the number one share gainer in the U.S. beer industry driven by accelerating Corona brand family dollar trends and Modelo Especial’s position as the top share gainer in the market. Corona brand family trends accelerated from 4% depletion growth in fiscal 2018 to 8% for this year’s first half driven by the successful launches of the Corona Premier and Corona Familiar product introductions, both of which have significantly exceeded our expectations. Corona Premier has achieved record speed-to-shelf and has become the 10th largest brand in the high-end and the number one high-end share gainer in very, very short order. The incrementality rate for Corona Premier is best-in-class for the launch of a new consumer product, with almost 75% of Corona Premier volume being sourced outside the Constellation beer portfolio, mostly from domestic light beers. The Corona Premier English and Spanish language TV campaigns that aired throughout the first half of the year will continue into the fall to drive broad brand awareness during major league baseball as well as the NFL and NHL seasons. Corona Familiar also achieved a healthy share of the U.S. beer category and its regional expansion at a rate of about 50% incrementality for the brand with velocities outpacing our plans. Corona Extra continues to provide the strong foundation needed for the portfolio to grow with strong brand equity as the number one most loved brand among Hispanic and total population drinkers aged 21 to 54. There continues to be plenty of runway for future Corona Extra growth with incremental contributions from draft and canned format as well as the Cornita [ph] product, and we continue to see growing household penetration with Hispanic and non-Hispanic consumers. The Casa Modelo family of brands has been the number one growth driver in the U.S. beer category with a CAGR of almost 20% for the last 5 years. The Modelo Especial power brand with volume of 100 million cases last year continues to be on fire capturing not only the top spot as the number one growth brand but also the number one share gainer in the total U.S. beer industry during the second quarter. To sustain this incredible momentum, we are increasing the media investment for Modelo Especial in the second half to drive additional demand especially during the football season and the holidays. During the quarter, we purchased Four Corners Brewing, local Dallas craft brewery whose bicultural brand, inspired flavors, capitalized on one of the hottest trends in beer, Hispanic influenced products. This high performing brand has grown sales 5x since 2014. Our new brand entrants in test markets within the alternative beverage alcohol space are doing exceptionally well as a growing market opportunity that has been incremental to the beer category. Corona Refresca is exceeding our expectations in current test markets with early indicators suggesting that this product is at least 80% incremental to our portfolio. As a result, we are planning a phased national rollout beginning next spring with the focus on retail chain space. And the new SVEDKA Spiked Premium Seltzer, which is also seeing excellent results in Northeast test markets has planned and expanded rollout next spring in select markets. From an operational perspective, during the quarter we continued the new expansion phase at our Obregon brewery with detailed design and site work in various phases of completion. The phase – the final phase of the 30 million hectoliter expansion project at Nava is on track as we add capacity for production, fermentation, and filtration with completion planned for the end of fiscal 2019. Our Nava glass plant, which we are already underway with work on, the batch house and furnace foundation in anticipation of the build-out of furnace #5 which we expect to complete by the end of calendar 2019, and construction continues at Mexicali with warehouse and packaging buildings nearly complete. Overall, I am excited about the existing momentum and the ongoing growth prospects for our beer business. We remain committed to delivering industry-leading targets for this business with net sales and operating income growth in the 9% to 11% range for fiscal 2019. Moving to wine and spirits, our wine and spirits business benefited from strong shipment volume growth in the second quarter to ensure that the portfolio is well positioned for a head start to our peak selling period when we believe that freight lanes may be in short supply. We are performing particularly well in the greater than $11 price point at retail, a level that is driving much of the overgrowth – overall growth in the U.S. wine industry. Our attention to this higher retail price point is paying off as we posted depletion growth of more than 6% for this price segment during the second quarter with Meiomi, Kim Crawford, SIMI, and Prisoner Focus Brands all posting solid growth trends. I would like to remind everyone that our total Focus Brands portfolio currently represents more than 70% of the net sales and profitability for the wine and spirits business. This collection of brands has also consistently grown at a rate of 3x to 4x the U.S. market rate. Our high-end spirits brands like High West, which is also included in our Focus Brands delivered accelerating depletion growth of almost 35% for the quarter driven by American Prairie Reserve and Double Rye! with Casa Noble tequila posting second quarter depletion growth of almost 15%. Current initiatives are also driving growth with successes like Clos du Bois Lightly Bubbled Chardonnay, Black Box Sangria, and our collection of newly introduced Rose brands, including Meiomi, Kim Crawford, and Band of Roses. Our innovation pipeline is already planned for the upcoming holiday selling season with new brands like Meiomi Sparkling, Cooper & Thief Rye Barrel Aged Cabernet, The Snitch, a new Prisoner brand chardonnay as well as Black Box spirits which will continue to expand in the phase rollout. While our fiscal 2019 wine and spirits guidance of net sales and operating income growth of 2% to 4% range remains intact, we’re facing some challenges with the low end of our portfolio that make our targets challenging to achieve. The U.S. wine market is slow particularly at the less than 11% retail price point and our non-Focus Brands are in decline. Therefore, while we continue to focus on initiatives to drive growth at the higher end, we’re also developing plans and considering options to optimize value at the low end of the portfolio so that we can direct our innovation and investment dollars to Focus Brands particularly those at the greater than $11 price point. We have plans in place for the remainder of the year to improve our COGS management capabilities with planned initiatives for yield improvement, production efficiencies, blend optimization and procurement savings. We expect these initiatives to offset some of the headwinds we continue to face including higher transportation and credit costs. In addition, we will continue to support our innovation plans and brand building efforts throughout the remainder of the year especially during the key holiday selling season with impactful marketing campaigns to strengthen and build the portfolio. Now before turning the call over to David, I’d like to take a few minutes to walk you through the strategic rationale and highlights of Constellation’s pending investment in Canopy Growth and why we believe that Canopy is the best partner to align with in the cannabis space. With our focus on continuous growth, we’ve recognized the significant opportunity that the emerging cannabis space presents as potentially one of the most significant global growth opportunities of the next decade. Our incremental $4 billion investment increases our interest in Canopy to approximately 35% and include warrants that provide us with the option to take our ownership position to greater than 50% over time. This will be the largest investment to-date in the cannabis space, a market which is expected to reach more than $200 billion in retail sales globally within the next 15 years and one that is opening up much more rapidly than originally anticipated. So why Canopy Growth? Canopy is the largest publicly traded cannabis supplier in the world and the leader in the medical cannabis market in Canada. We work closely with Canopy throughout the last year to better understand the cannabis market, the unbelievable opportunity it presents and Canopy’s market-leading capabilities in the space. With world-class expertise in R&D, innovation, product development, scaled production and international expansion, Canopy is poised to capitalize on the emerging global cannabis opportunity. They have already established a global presence via numerous joint ventures and partnerships. Canopy Growth has the largest legal cannabis production footprint in the world and in Canada, and they are the only producer currently participating in all Canadian provinces. They also have been awarded approximately 35% of the supply contracts announced throughout all Canadian provinces to-date that are dedicated to recreational cannabis, a market that will become legal in Canada later this month. Going forward, we will be working exclusively with Canopy as we believe that having a single platform to address all markets and formats globally is essential to winning in this space. Canopy plans to use the investment proceeds to bolster their global leadership position in the Canopy – cannabis industry by building or acquiring key assets needed to establish global scale. Strategic priorities beyond Canada include the U.S. in the nearly 30 countries presently pursuing a federally permissible medical cannabis program. In addition, Canopy plans to focus on intellectual property development across medical and recreational opportunities while also preparing and creating brands and products for new recreational cannabis markets. Canopy has a portfolio of the most recognized cannabis brands in Canada and they are building a suite of new offerings across various product formats that will be sold through new and existing channels. A strong online platform currently supports Canopy’s ongoing direct to patient medical business and they are building a network of brick-and-mortar stores across Canada as they ramp up for participation in the legalized recreational market. Canopy’s shareholders recently approved their pending transaction and I look forward to working with Bruce Lin and his Canopy team who have built a phenomenal business. As the growth leader in total beverage alcohol space, we expect to reap the benefits of our cannabis investment, which we see as being incremental to our core beer, wine and spirits portfolio. I am very excited about the excellent prospects for this business as the global cannabis space emerges. In summary, I am pleased that we have been able to increase our EPS guidance range for the year based on our year-to-date results and the plans we have in place for the remainder of the year. Given Constellation’s leadership position in the high-end U.S. beer market further runway for margin expansion throughout the business, unique leverage to the emerging cannabis space and an attractive valuation, I believe Constellation will continue to be a multiyear double-digit EPS compounder. With that, I would now like to turn the call over to David who will review our financial results for the quarter. David?